Population-based cohort follow-up study of all patients operated for borderline ovarian tumor in western Sweden during an 11-year period

International Journal of Gynecological Cancer

Volumn 18, Issue 3, 2008, Pages 453-459

  Akeson M ^a,b   Zetterqvist, B M ^c   Dahllof K ^d   Jakobsen, A M ^d   Brannstrom M ^d   Horvath, G ^d  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b BORÅS HOSPITAL   (Sweden)

^c Trollhattan Hospital   (Sweden)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Low malignant potential; Ovarian neoplasm; Quality register; Recurrence; Survival

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; PLATINUM DERIVATIVE;

ADOLESCENT; ADULT; AGED; ANEUPLOIDY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY TUMOR; PLOIDY; POPULATION RESEARCH; PRIORITY JOURNAL; SWEDEN; TREATMENT INDICATION; TREATMENT OUTCOME;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; INCIDENCE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; OVARIECTOMY; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; SWEDEN; TREATMENT OUTCOME;

EID: 43449137559     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.01051.x     Document Type: Article

References (32)

1. Prat J. Ovarian tumors of borderline malignancy (tumors of low malignant potential): a critical appraisal. Adv Anat Pathol 1999 6 : 247 74.
2. Serov SF, Scully SR, Sobin LH. International histological typing of ovarian tumors. No 9. Histologic typing of ovarian tumors. Geneva, Switzerland : WHO, 1973.
3. Trimble CL, Kosary C, Trimble EL. Long-term survival and patterns of care in women with ovarian tumors of low malignant potential. Gynecol Oncol 2002 86 : 34 7.
4. Sherman ME, Mink PJ, Curtis R et al. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis. Cancer 2004 100 : 1045 52.
5. Longacre TA, McKenney JK, Tazelaar HD et al. Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or = 5-year) follow-up. Am J Surg Pathol 2005 29 : 707 23.
6. Seidman JD, Kurman RJ. Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. Hum Pathol 2000 31 : 539 57.
7. Riman T, Dickman PW, Nilsson S et al. Risk factors for epithelial borderline ovarian tumors: results of a Swedish case-control study. Gynecol Oncol 2001 83 : 575 85.
8. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992 136 : 1184 203.
9. Harris R, Whittemore AS, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. III. Epithelial tumors of low malignant potential in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992 136 : 1204 11.
10. Marcickiewicz J, Brannstrom M. Fertility preserving surgical treatment of borderline ovarian tumour: long-term consequence for fertility and recurrence. Acta Obstet Gynecol Scand 2006 85 : 1496 500.
11. Kaern J, Trope CG, Kristensen GB et al. DNA ploidy; the most important prognostic factor in patients with borderline tumors of the ovary. Int J Gynecol Cancer 1993 3 : 349 58.
12. Akeson M, Zetterqvist BM, Holmberg E, Horvath G. Improved survival with clinical guidelines? Evaluation of a quality register linked to clinical guidelines for ovarian cancer in the western health care region in Sweden between 1 September 1993 and 1 June 1998. Acta Obstet Gynecol Scand 2005 84 : 1113 8.
13. Thornthwaite JT, Sugarbaker EV, Temple WJ. Preparation of tissues for DNA flow cytometric analysis. Cytometry 1980 1 : 229 37.
14. Lee GM, Thornthwaite JT, Rasch EM. Picogram per cell determination of DNA by flow cytofluorometry. Anal Biochem 1984 137 : 221 6.
15. Hiddemann W, Schumann J, Andreef M et al. Convention on nomenclature for DNA cytometry. Committee on Nomenclature, Society for Analytical Cytology. Cancer Genet Cytogenet 1984 13 : 181 3.
16. Andersson H, Friberg LG, Horvath G et al. Carboplatin in combination with epirubicin and cyclophosphamide in patients with advanced ovarian cancer. A phase II study. Acta Oncol 1995 34 : 821 7.
17. http://www.pauldickman.com accessed July 2007 J, Trope CG, Abeler VM. A retrospective study of 370 borderline tumors of the ovary treated at the Norwegian Radium Hospital from 1970 to 1982. A review of clinicopathologic features and treatment modalities. Cancer 1993 71 : 1810 20.
18. Trope C, Kaern J. Management of borderline tumors of the ovary: state of the art. Semin Oncol 1998 25 : 372 80.
19. Zanetta G, Rota S, Chiari S et al. Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. J Clin Oncol 2001 19 : 2658 64.
20. Levi F, La Vecchia C, Randimbison L, Te VC. Borderline ovarian tumours in Vaud, Switzerland: incidence, survival and second neoplasms. Br J Cancer 1999 79 : 4 6.
21. Acs G. Serous and mucinous borderline (low malignant potential) tumors of the ovary. Am J Clin Pathol 2005 123 (Suppl. S13 57.
22. Auranen A, Grenman S, Makinen J et al. Borderline ovarian tumors in Finland: epidemiology and familial occurrence. Am J Epidemiol 1996 144 : 548 53.
23. Buttini M, Nicklin JL, Crandon A. Low malignant potential ovarian tumours: a review of 175 consecutive cases. Aust N Z J Obstet Gynaecol 1997 37 : 100 3.
24. Leake JF, Currie JL, Rosenshein NB, Woodruff JD. Long-term follow-up of serous ovarian tumors of low malignant potential. Gynecol Oncol 1992 47 : 150 8.
25. Barnhill DR, Kurman RJ, Brady MF et al. Preliminary analysis of the behavior of stage I ovarian serous tumors of low malignant potential: a Gynecologic Oncology Group study. J Clin Oncol 1995 13 : 2752 6.
26. Longacre TA, Kempson RL, Hendrickson MR. Serous tumours of low malignant potential (serous borderline tumours): moving toward detente. Histopathology 2005 47 : 315 8.
27. Kurman RJ, Seidman JD, Shih IM. Serous borderline tumours of the ovary. Histopathology 2005 47 : 310 5.
28. Harlow BL, Fuhr JE, McDonald TW et al. Flow cytometry as a prognostic indicator in women with borderline epithelial ovarian tumors. Gynecol Oncol 1993 50 : 305 9.
29. Seidman JD, Norris HJ, Griffin JL, Hitchcock CL. DNA flow cytometric analysis of serous ovarian tumors of low malignant potential. Cancer 1993 71 : 3947 51.
30. Demirel D, Laucirica R, Fishman A et al. Ovarian tumors of low malignant potential. Correlation of DNA index and S-phase fraction with histopathologic grade and clinical outcome. Cancer 1996 77 : 1494 500.
31. Fort MG, Pierce VK, Saigo PE et al. Evidence for the efficacy of adjuvant therapy in epithelial ovarian tumors of low malignant potential. Gynecol Oncol 1989 32 : 269 72.
32. Barakat RR, Benjamin I, Lewis JL Jr. et al. Platinum-based chemotherapy for advanced-stage serous ovarian carcinoma of low malignant potential. Gynecol Oncol 1995 59 : 390 3.